secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001104659-23-068579
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Biotherapeutics shareholders approve all six proposals at 2023 annual meeting
--------------------------------------------------------------------------------

- All seven director nominees elected; Wendy Dixon did not stand for re-election (no disagreement).
- Advisory vote on executive compensation approved (152.1M for, 18.0M against).
- Ratification of Ernst & Young as auditor approved (189.1M for).
- Amendment to 2018 Equity Incentive Plan: shares increased from 20.7M to 29.7M.
- ESPP shares increased from 500k to 1.4M; authorized common stock increased from 300M to 500M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/tm2317979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-068579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer